彩色多普勒超声在原发性肝癌介入治疗中的应用与评价.研究

《彩色多普勒超声在原发性肝癌介入治疗中的应用与评价.研究》由会员上传分享，免费在线阅读，更多相关内容在应用文档-天天文库。

1、山东大学硕士学位论文THEAPPLICATIONANDAPPRAISALOFCOLORDOPPLERULTRASONOGRAPHYINPRIMARYHEPATICCARCINOMABYINTERVENTl0NALTHERAPYPostgraduateliManTutorKangYongJunAbstract【Objective1TostudytheclinicalvalueandtherapeuticeffectofcolorDopplerU1tras。nographyinprimaryhepaticcarci

2、nomabythesizeoftumor、thebloodsupplyandthechangesofhemodynamicsofproperhepaticarteryandportalveinbeforeandaftertranscatheterarterychemoembolization(TACE)、TACEcombinedpercutaneouslipiodolinjection(PLI)andTACEcombinedpercutaneousethanalinjection(PEL)，tofindoutt

3、hebestguidelinetoevaluatetheefficacyandthebesttherapeuticmethod【Methods】139casesofPHCweredividedintotwogroups．70casesweretreatedwithTACE，26casesweretreatedwithTACEandfollowedbyPLl，43casesweretreatedwithTACEandfollowedbyPEI．AllcasesexaminedbyCDUonedaybefo,‘e、

4、oneweekafter、twoweeksafterandeverymonthaftertherapyIncluded：thediameteroftumor、thesonographiccharacteristicsoftumor、thebloodsupply、thehemodynamicchangesofproperhepaticarteryandthehemodynamicchangesofportalveJn．DetermineAFPatthesameIime．Judgethetherapeuticeff

5、ectbypathologicaleffectafterre-operationandbiopsy，Judgethelong—termtherapeuticeffectbyfollow-upsurvivalrate．3山东大学硕士学位论文【Results】Threegroupsaftertherapy：AFP、thediameteroftumor、thebloodsupplyOftumorandtheVmaxofproperhepaticarteryweredecreased(p<0．05)．RIofprope

6、rhepaticarterywereincreased(p<0．05)，thediameter、thetimeaveragevelocityandthevolumeofbloodflowofportalveindidnotchangesignificantly。The6-rnonth、1一、2一、3一yearsurvivalratesofgroupTACEwere61．4％、42．9％、186％、8。5％．The6-month、1yearsurvivalratesofgroupTACE+PLlwere80．8％

7、、73．1％The6-month、1yearsurvivalratesofgroupTACE+PElwere86．4％、74．4％AFPcorrelatedwiththebloodsupplyoftumor、theVmaxofproperhepaticarteryandRI，AFPhavenocorrelationwiththediameter、thetimeaveragevelocityandthevolumeofbloodflowofportalvein。TherateofAFPturnedfromposi

8、tivetonegative、thediameteroftumor、thebloodsupplyoftumor、thediameterofproperhepaticartery、theVmaxandRIhavenoobviousdifference(p>0．05)betweengroupTACE+PLIandgroupTACE+PEI．TherateofAFPturnedfrompos